A c5a receptor antagonist is reported to decrease tau hyperphosphorylation in 3xTg mouse model of Alzheimer’s disease [24], while surfen also acts as an inhibitor of c5a receptor binding [10]. This evidence concerns the gene MAPT and early-onset autosomal dominant Alzheimer disease.